ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy alone
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further ...
Oct 23, 2023
0
0